Treatment with angiogenesis inhibitors frequently shows promising results in a wide spectrum of metastatic cancers (reviewed
in Meadows et al
1
). Hence, attention to specific side effects is of great interest.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Anti-VEGF therapies in the clinic.Cold Spring Harb Perspect Med. 2012; 2
- Visceral artery aneurysm: risk factor analysis and therapeutic opinion.Eur J Vasc Endovasc Surg. 2007; 33: 293-301
- Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition.Nat Rev Cancer. 2007; 7: 475-485
- Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.J Clin Oncol. 2012; 30: 871-877
- VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis.Proc Natl Acad Sci U S A. 2006; 103: 17260-17265
Article info
Publication history
Published online: December 30, 2013
Accepted:
December 19,
2013
Identification
Copyright
© 2014 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
